1. Home
  2. IRD vs MDCX Comparison

IRD vs MDCX Comparison

Compare IRD & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • MDCX
  • Stock Information
  • Founded
  • IRD 2018
  • MDCX 2008
  • Country
  • IRD United States
  • MDCX Canada
  • Employees
  • IRD 14
  • MDCX N/A
  • Industry
  • IRD
  • MDCX
  • Sector
  • IRD
  • MDCX
  • Exchange
  • IRD NYSE
  • MDCX Nasdaq
  • Market Cap
  • IRD 36.0M
  • MDCX 33.8M
  • IPO Year
  • IRD N/A
  • MDCX N/A
  • Fundamental
  • Price
  • IRD $1.16
  • MDCX $2.91
  • Analyst Decision
  • IRD Strong Buy
  • MDCX Strong Buy
  • Analyst Count
  • IRD 1
  • MDCX 1
  • Target Price
  • IRD $8.00
  • MDCX $10.00
  • AVG Volume (30 Days)
  • IRD 147.6K
  • MDCX 9.2K
  • Earning Date
  • IRD 02-19-2025
  • MDCX 01-01-0001
  • Dividend Yield
  • IRD N/A
  • MDCX N/A
  • EPS Growth
  • IRD N/A
  • MDCX N/A
  • EPS
  • IRD N/A
  • MDCX N/A
  • Revenue
  • IRD $8,381,000.00
  • MDCX N/A
  • Revenue This Year
  • IRD N/A
  • MDCX N/A
  • Revenue Next Year
  • IRD $29.37
  • MDCX N/A
  • P/E Ratio
  • IRD N/A
  • MDCX N/A
  • Revenue Growth
  • IRD N/A
  • MDCX N/A
  • 52 Week Low
  • IRD $0.81
  • MDCX $1.80
  • 52 Week High
  • IRD $2.77
  • MDCX $3.23
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • MDCX N/A
  • Support Level
  • IRD N/A
  • MDCX N/A
  • Resistance Level
  • IRD N/A
  • MDCX N/A
  • Average True Range (ATR)
  • IRD 0.00
  • MDCX 0.00
  • MACD
  • IRD 0.00
  • MDCX 0.00
  • Stochastic Oscillator
  • IRD 0.00
  • MDCX 0.00

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About MDCX Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Share on Social Networks: